Enhancement of the immunogenicity of a
HspX/EsxS
ISCOMATRIX
MPLA
Mycobacterium
Nasal administration
PLUSCOM
tuberculosis
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
2024
2024
Historique:
received:
30
11
2022
accepted:
05
08
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
2
1
2024
Statut:
ppublish
Résumé
Tuberculosis (TB), a contagious disease caused by In the present study, the recombinant fusion protein was expressed in Escherichia coli and purified and used to prepare different nanoparticle formulations in combination with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA. Mice were intranasally vaccinated with each formulation three times at an interval of 2 weeks. Three weeks after the final vaccination, IFN-γ, IL-4. IL-17, and TGF-β concentrations in the supernatant of cultured splenocytes of vaccinated mice as well as serum titers of IgG1 and IgG2a and sIgA titers in nasal lavage were determined. According to obtained results, intranasally vaccinated mice with formulations containing ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA could effectively induce IFN-γ and sIgA responses. Moreover, both HspX/EsxS/ISCOMATRIX/MPLA and HspX/EsxS/PLUSCOM/MPLA and their BCG booster formulation could strongly stimulate the immune system and enhance the immunogenicity of The results demonstrate the potential of HspX/EsxS-fused protein in combination with ISCOMATRIX, PLUSCOM, and MPLA after nasal administration in enhancing the immune response against
Identifiants
pubmed: 38164481
doi: 10.22038/IJBMS.2023.69295.15100
pmc: PMC10722485
doi:
Types de publication
Journal Article
Langues
eng
Pagination
24-30Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Iran J Basic Med Sci. 2019 Aug;22(8):893-900
pubmed: 31579445
J Control Release. 2015 Dec 10;219:596-609
pubmed: 26254198
Microb Pathog. 2021 May;154:104842
pubmed: 33762199
APMIS. 2018 Jun;126(6):509-514
pubmed: 29924445
PLoS One. 2014 Nov 14;9(11):e112848
pubmed: 25398087
J Med Microbiol. 2012 Jul;61(Pt 7):935-943
pubmed: 22442293
PLoS One. 2015 Mar 30;10(3):e0122560
pubmed: 25822536
Expert Rev Vaccines. 2018 Jan;17(1):31-44
pubmed: 29148853
Immunol Cell Biol. 2009 Jul;87(5):371-6
pubmed: 19381160
Semin Immunol. 2013 Apr;25(2):172-81
pubmed: 23706597
Vaccine. 2013 Jan 21;31(5):735-49
pubmed: 23219436
Indian J Tuberc. 2019 Oct;66(4):487-491
pubmed: 31813436
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890836
PLoS One. 2016 May 05;11(5):e0154757
pubmed: 27149269
Vaccine. 2008 Aug 18;26(35):4549-56
pubmed: 18585421
Microb Pathog. 2018 Dec;125:507-513
pubmed: 30352265
Microb Pathog. 2018 Aug;121:218-223
pubmed: 29800697
Rep Biochem Mol Biol. 2017 Oct;6(1):15-21
pubmed: 29090225
Iran J Basic Med Sci. 2018 Feb;21(2):116-123
pubmed: 29456807
Mol Immunol. 2015 Aug;66(2):392-401
pubmed: 25974877
Iran J Immunol. 2015 Dec;12(4):274-87
pubmed: 26714419
Expert Rev Vaccines. 2007 Oct;6(5):761-72
pubmed: 17931156
J Pharm Sci. 2005 Aug;94(8):1794-807
pubmed: 15986471
Appl Microbiol Biotechnol. 2015 Dec;99(24):10467-80
pubmed: 26373723
Pneumonia (Nathan). 2016 Apr 12;8:1
pubmed: 28702281